Results 51 to 60 of about 2,643,317 (205)

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV [PDF]

open access: yes, 2014
The impact of imatinib dose on response rates and survival in older patients with chronic myeloid leukemia in chronic phase has not been studied well. We analyzed data from the German CML-Study IV, a randomized five-arm treatment optimization study in ...
Annette Schreiber   +467 more
core   +2 more sources

Cerebral localization of chronic myelomonocytic leukemia: a case report

open access: yesJournal of Medical Case Reports, 2021
Background Chronic myelomonocytic leukemia is a myelodysplastic/myeloproliferative neoplasm characterized by the infiltration of blood and bone marrow by immature monocytes.
Clémence Haméon   +7 more
doaj   +1 more source

A Case of Leukemic Pleural Infiltration in Atypical Chronic Myeloid Leukemia [PDF]

open access: yesJournal of Korean Medical Science, 2006
Pleural effusion in chronic myeloid leukemia (CML) is poorly understood and rarely reported in the literature. When the pleural effusion is caused by leukemic pleural infiltration, the differential white blood cell count of the effusion is identical to that of the peripheral blood, and the fluid cytology reveals leukemic blasts.
Kim, Hyun Woo   +9 more
openaire   +2 more sources

Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac   +16 more
wiley   +1 more source

Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia

open access: yesLeukemia Research Reports, 2014
Mutations in CSF3R (colony-stimulating factor 3 receptor) are frequent oncogenic drivers in chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML).
Kim-Hien T. Dao   +6 more
doaj   +1 more source

Bone marrow‐like viscosity affects imatinib resistance in chronic myeloid leukemia

open access: yesBiotechnology Progress, EarlyView.
Physical cues such as microenvironmental viscosity have been recognized as important regulators in controlling cell functions. However, even though the bone marrow (BM) is a viscous tissue in which cells respond mechanically to both the matrix stiffness and the viscosity of surrounding fluid, the impact of microenvironmental viscosity on imatinib (IM ...
Tianjiao Zeng   +6 more
wiley   +1 more source

CSF3R T618I mutated chronic myelomonocytic leukemia: A proliferative subtype with a distinct mutational profile

open access: yesLeukemia Research Reports, 2022
Chronic myelomonocytic leukemia (CMML) is a clonal myeloid neoplasm characterized by sustained monocytosis and mutations in TET2, ASXL1, SRSF2, SETBP1, NRAS, and KRAS. We describe a rare case of CSF3R T618I mutated CMML that has a proliferative phenotype,
Adelaide Kwon   +6 more
doaj   +1 more source

A case series of necrotizing periodontal diseases in hospitalized patients: What hasn't been said yet?

open access: yesClinical Advances in Periodontics, EarlyView.
Abstract Background Necrotizing periodontal diseases (NPDs) are uncommon and severe inflammatory conditions characterized by tissue necrosis, painful ulceration, and rapid clinical progression, frequently associated with systemic immunosuppression. Limited data exist regarding their clinical presentation and management in hospital settings.
Osmaria Letthycia Carvalho Leal   +8 more
wiley   +1 more source

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells [PDF]

open access: yes, 2011
Chronic myeloid leukaemia (CML) is maintained by a rare population of tyrosine kinase inhibitor (TKI)-insensitive malignant stem cells. Our long-term aim is to find a BcrAbl-independent drug that can be combined with a TKI to improve overall disease ...
E K Allan   +7 more
core   +1 more source

Unravelling the mechanisms of resistance to imatinib mesylate in chronic myeloid leukemia: a proteomic approach [PDF]

open access: yes, 2010
Imatinib mesylate is a potent inhibitor of the Bcr-Abl tyrosine kinase, an oncoprotein that plays a key role in the development of chronic myeloid leukemia. Consequently, imatinib is used as front-line therapy for this disease.
Colavita, Irene
core   +1 more source

Home - About - Disclaimer - Privacy